BRAIN Biotech AG (HAM:BNN) Total Stockholders Equity: €-7.12 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BNN BRAIN Biotech AG HAM:BNN
64 GF Score
Price €2.76
GF Value €2.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Total Stockholders Equity?

BRAIN Biotech AG HAM:BNN -4.50% 64 Total Stockholders Equity is €-7.12 Mil as of Jun. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 64/100 and a GF Value™ of €2.49 (Modestly Overvalued). The stock has 3 warning signs investors should review.

BRAIN Biotech AG's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €-7.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BRAIN Biotech AG's Book Value per Share for the quarter that ended in Jun. 2026 was €-0.33. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BRAIN Biotech AG's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

BRAIN Biotech AG  (HAM:BNN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BRAIN Biotech AG's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-7.121-0)/21.847
=-0.33

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BRAIN Biotech AG's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -7.121
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Total Stockholders Equity Related Terms

BRAIN Biotech AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Total Stockholders Equity Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.78 29.64 21.77 12.62 1.84

BRAIN Biotech AG Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.35 9.04 5.00 -0.73 -7.12
HAM:BNN
64GF Score
BRAIN Biotech AG HAM:BNN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €-7.12 Mil mean?
BRAIN Biotech AG (HAM:BNN) has a Total Stockholders Equity of €-7.12 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Total Stockholders Equity too high?
BRAIN Biotech AG's current Total Stockholders Equity is €-7.12 Mil. Overall, BRAIN Biotech AG has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Total Stockholders Equity compare to LIN and SHW?
BRAIN Biotech AG's Total Stockholders Equity of €-7.12 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Chemicals company?
A good Total Stockholders Equity depends on the Chemicals industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Total Stockholders Equity is €-7.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.49, compared to a current price of €2.76 — trading 10.8% above its estimated fair value. The current Total Stockholders Equity is €-7.12 Mil. BRAIN Biotech AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Total Stockholders Equity is €-7.12 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.76 is trading 10.8% above its estimated GF Value™ of €2.49. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

  • Total Stockholders Equity: €-7.12 Mil
  • GF Value™: €2.49 vs. price of €2.76 (10.8% above fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
64GF Score

Get the complete analysis for HAM:BNN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price
€2.49
GF Value